Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2015; 21(39): 10936-10947
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.10936
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.10936
Evaluation and treatment of malignant ascites secondary to gastric cancer
Hiromichi Maeda, Michiya Kobayashi, Cancer Treatment Center, Kochi Medical School, Kochi 783-8505, Japan
Junichi Sakamoto, Tokai Central Hospital, Sohara Higashijima-cho, Kakamigahara 504-8601, Japan
Author contributions: Maeda H wrote the manuscript; Kobayashi M and Sakamoto J contributed to conception of this study and revised the draft.
Supported by Non-profit Epidemiological and Clinical Research Organization.
Conflict-of-interest statement: There is no conflict of interest to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Junichi Sakamoto, MD, PhD, Tokai Central Hospital, Sohara Higashijima-cho, Kakamigahara, Gifu 504-8601, Japan. sakamjun@tokaihp.jp
Telephone: +81-58-3823101 Fax: +81-58-3820229
Received: April 23, 2015
Peer-review started: April 24, 2015
First decision: July 13, 2015
Revised: July 26, 2015
Accepted: September 13, 2015
Article in press: September 13, 2015
Published online: October 21, 2015
Peer-review started: April 24, 2015
First decision: July 13, 2015
Revised: July 26, 2015
Accepted: September 13, 2015
Article in press: September 13, 2015
Published online: October 21, 2015
Core Tip
Core tip: Malignant ascites affects approximately 10% of patients with gastric cancer (GC) and poses significant problems for treatment. Accurate and repetitive measurement of ascites volume during treatment is clinically imperative for effective decisions surrounding treatment continuation. Meanwhile, clinical benefit response in GC, a patient-oriented assessment framework of treatment efficacy, should be used in future clinical trials for malignant ascites caused by GC. Although several treatment options have been reported, further studies are mandatory to develop a solid and optimal treatment strategy.